About Shire

We’re with you.

Longer than any other manufacturer, Shire* has been a reliable and consistent supplier of IgG treatment.1

Through Growth and Transition

Shire's* investments in plasma treatment processing have grown from $614 million to $1.2 billion in recent years, and Shire is committed to continued investment in the future.1

With more than 85 state-of-the-art plasma collection centers, Shire collects nearly 5 million liters of source plasma each year to meet the needs of those who rely on plasma-based treatment.2,3 Shire also has the largest fractionation capacity among all plasma manufacturers and plans to build a new facility that will add up to 3 million liters of fractionation capacity annually when fully functional.1

With Education and Support

Shire offers unprecedented support and a wealth of educational resources, created with the help of patients, caregivers, and healthcare professionals from the community. Support is offered without charge to patients and caregivers, regardless of treatment.

Yesterday, Today, and Tomorrow

Shire plc* became a leader in plasma fractionation in 1941 and is the only company that has been continuously processing IVIG for more than 30 years.4,5 Our aim is to provide the highest quality products and programs that advance patient care globally and enable the achievement of outcomes through innovation, science, and technology.

*Shire plc bought Baxalta Incorporated in 2016. Baxalta Incorporated was formerly the BioScience Division at Baxter International Inc. and continues to provide those same treatments and products.

References

  1. Baxter's International Inc. 2012 Annual Report.
  2. BioLife Press Kit. http://biolifeplasma.com/downloads/biolife-press-kit.pdf. Accessed May 24, 2017.
  3. BioLife plasma donation centers. https://www.biolifeplasma.com/us/#/about-biolife/our-centers. Accessed October 1, 2016.
  4. Baxer's history. Baxter website. http://www.baxter.com/inside-baxter/about/overview/company-history.page. Accessed June 17, 2017.
  5. Marketing Research Bureau. The Plasma Proteins Market in the United States 2015. Orange, CT: Marketing Research Bureau, Inc.; 2016.
Expand

Please expand for Indication and Detailed Important Safety Information.

Selected Important Safety Information about GAMMAGARD LIQUID
  • GAMMAGARD LIQUID can cause decreased kidney function or kidney failure, blood clots in the heart, brain, lungs or elsewhere in the body. Call your healthcare professional or go to your emergency department right away if you have: Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem. Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.
  • Do not take GAMMAGARD LIQUID if you have a known history of a severe allergic reaction to IgG or other blood products.